Firm eyes up £38bn market
AVACTA SAID antibodies dominate markets worth over £38bn despite their shortcomings.
Its Affimer technology has been designed to address many of these negative performance issues, including the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability.
Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders.